Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Coronavirus company news summary – J&J vaccine rollout to resume in Europe after EMA blood clots review – Moderna signs 2022 vaccine supply agreement with Israel

21 Apr 2021 (Last Updated April 21st, 2021 09:54)

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has provided new updates and guidance for the use of Johnson & Johnson’s Covid-19 vaccine and has established that its benefit-risk profile remains positive. The guidance comes after reported cases of blood clots combined with low platelet counts among individuals, one to three weeks after receiving the vaccine. The company will restart delivery of the Janssen Covid-19 vaccine in the European Union (EU), Iceland and Norway, with updated labelling on the diagnosis and management of rare blood clotting events.

Moderna has signed a new supply agreement with Israel for 2022. Under the terms of the agreement, Israel now holds the option to purchase Moderna’s variant-specific vaccine doses, following regulatory approval. Israel and Moderna have two prior agreements for the supply of 10 million doses of COVID-19 Vaccine Moderna. Israel’s health ministry approved the use of Moderna’s vaccine on 4 January 2021.

Swiss-based biopharmaceutical company Debiopharm has partnered with InnoCentive, an open innovation crowdsourcing platform, to develop a single-dose preparation of approved messenger RNA (mRNA) Covid-19 vaccines through the InnoCentive network of “problem solvers”. Debiopharm has launched the collaborative vaccine challenge to identify new formulations for a single-injection mRNA vaccine that can provide the same efficacy and protection as approved multi-dose formulations can provide.